Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Inhibitory antibodies to factor VIII (FVIII) are a major complication in the treatment of hemophilia A, affecting approximately 20% to 30% of patients. Current treatment for inhibitors is based on long-term, daily injections of large amounts of FVIII protein. Liver-directed gene therapy has been used to induce antigen-specific tolerance, but there are no data in hemophilic animals with pre-existing inhibitors. To determine whether sustained endogenous expression of FVIII could eradicate inhibitors, we injected adeno-associated viral vectors encoding canine FVIII (cFVIII) in 2 strains of inhibitor hemophilia A dogs. In 3 dogs, a transient increase in inhibitor titers (up to 7 Bethesda Units [BU]) at 2 weeks was followed by continuous decline to complete disappearance within 4-5 weeks. Subsequently, an increase in cFVIII levels (1.5%-8%), a shortening of clotting times, and a reduction (> 90%) of bleeding episodes were observed. Immune tolerance was confirmed by lack of antibody formation after repeated challenges with cFVIII protein and normal protein half-life. A fourth dog exhibited a strong early anamnestic response (216 BU), with slow decline to 0.8 BU and cFVIII antigen detection by 18 months after vector delivery. These data suggest that liver gene therapy has the potential to eradicate inhibitors and could improve the outcomes of hemophilia A patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been shown in multiple preclinical (160, 168 -171) and clinical studies (34) that liver-targeted AAV delivery induced immune tolerance of transgene products.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [168]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Hauswirth, W. W., Aleman, T. S., Kaushal, S., Cideciyan, A. V., Schwartz, S. B., Wang, L., Conlon, T. J., Boye, S. L., Flotte, T. R., Byrne, B. J., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.107 · Cited by 954
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationABNORMAL HISTIDINE METABOLISM IN THYROTOXICOSIS IN MAN
Mohamed, S. D., & Roberts, M. (1965) · The Lancet · doi:10.1016/s0140-6736(65)92906-5 · Cited by 623
Mohamed, S. D., & Roberts, M. (1965) · PubMed · Cited by 612
Herzog, R. W., Yang, E. Y., Couto, L. B., Hagstrom, J. N., Elwell, D., Fields, P. A., Burton, M., Bellinger, D. A., Read, M. S., Brinkhous, K. M., et al. (1999) · Nature Medicine · doi:10.1038/4743 · Cited by 554
Self-citationInduction of Immune Tolerance to Coagulation Factor IX Antigen by In Vivo Hepatic Gene Transfer
Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J. H., Wang, Y., Arruda, V. R., High, K. A., & Herzog, R. W. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16887 · Cited by 466
Self-citationFactor VIII gene inversions in severe hemophilia A: results of an international consortium study
Antonarakis, S., Rossiter, J., Young, M., Horst, J., de Moerloose, P., Sommer, S., Ketterling, R., Kazazian, H. J., Negrier, C., & Vinciguerra, C. (1995) · Blood · doi:10.1182/blood.v86.6.2206.bloodjournal8662206 · Cited by 354
Self-citation
Research works printed but not linked: 1
- Roberts, 2001, Hemophilia A and hemophilia B., 1639
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“…has also been used in hemophilic mice and dogs with neutralizing antibodies to clotting factors (both VIII and IX) to eradicate these antibodies 127,129 (clinically termed inhibitors), further underscoring the protolerogenic properties of liver gene transfer with these vectors and providing proof…”
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Immune Responses to Viral Gene Therapy Vectors
Shirley, J. L., de Jong, Y. P., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.01.001 · Cited by 788
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer
Costa Verdera, H., Kuranda, K., & Mingozzi, F. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.12.010 · Cited by 641
Metadata
- Authors
- Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., & Arruda, V. R.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Queen's University (CA)
- University of Pennsylvania (US)
- University of North Carolina at Chapel Hill (US)
- ORCID
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2010-12-23
- Volume
- 116
- Issue
- 26
- Pages
- 5842-5848
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3031380
- OpenAlex
- W1976158989
- Cited by
- 157
- References
- 52
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 13 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 15 · 2019: 11 · 2018: 14 · 2017: 13 · 2016: 12 · 2015: 14 · 2014: 10 · 2013: 9 · 2012: 8
- FWCI
- 5.60
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- U.S. Public Health Service (R2414L063098)
- Canadian Institutes of Health Research (MOP10912)
- National Heart, Lung, and Blood Institute (HL084220, HL083017, R01HL084220, R24HL063098, R01HL083017)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Hematology › Platelet Disorders and Treatments
- Keywords
- hemophilia A, factor VIII inhibitors, neutralizing antibodies, liver-directed gene therapy, adeno-associated virus vectors, canine model, antigen-specific tolerance, inhibitor eradication, secondary immune response
- MeSH terms
- Adenoviridae, Animals, Dogs, Factor VIII, Flow Cytometry, Genetic Vectors, Half-Life, Hemophilia A, Immune Tolerance, Liver, Male, Tissue Distribution, Genetic Therapy, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. https://app.cochat.ai/papers/10.1182/blood-2010-06-288001
- The paper
- Finn, J. D., Ozelo, M. C., Sabatino, D. E., Franck, H. W. G., Merricks, E. P., Crudele, J. M., Zhou, S., Kazazian, H. H., Lillicrap, D., Nichols, T. C., & Arruda, V. R. (2010). Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood. https://doi.org/10.1182/blood-2010-06-288001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.